A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries. STAAR generates worldwide revenue almost exclusively from sales of our Implantable Collamer Lenses, or “ICLs.
| Metric | TTM | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 239M | 239M | 314M | 322M | 239M | 230M |
| Net Income | -80M | -80M | -20M | 21M | 40M | 28M |
| EPS | $-1.62 | $-1.62 | $-0.41 | $0.43 | $0.80 | $0.56 |
| Free Cash Flow | -40M | -40M | -7.7M | -3.6M | 18M | 30M |
| ROIC | - | - | -5.2% | 8.0% | 41.6% | 42.2% |
| Gross Margin | 76.2% | 76.2% | 76.3% | 78.4% | 93.3% | 77.5% |
| Debt/Equity | 0.00 | - | 0.10 | 0.09 | 0.00 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -92M | -92M | -13M | 28M | 44M | 33M |
| Operating Margin | -38.3% | -38.3% | -4.0% | 8.7% | 18.3% | 14.5% |
| ROE | 0.0% | - | -5.2% | 5.9% | 13.4% | 12.0% |
| Shares Outstanding | 50M | 50M | 49M | 50M | 50M | 49M |
STAAR SURGICAL CO passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 21.7% with a gross margin of 80.3%. Total shareholder yield (buybacks) is 0.5%. At current prices, the estimated annualized return to fair value is +21.6%.
STAAR SURGICAL CO (STAA) has a 5-year average return on invested capital (ROIC) of 21.7%. This indicates strong capital allocation and a potential competitive advantage.
STAAR SURGICAL CO (STAA) has a market capitalization of $1.2B. It is classified as a small-cap stock.
STAAR SURGICAL CO (STAA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.53%.
STAAR SURGICAL CO (STAA) operates in the Ophthalmic Goods industry, within the Healthcare sector.
STAAR SURGICAL CO (STAA) reported annual revenue of $239 million in its most recent fiscal year, based on SEC EDGAR filings.
STAAR SURGICAL CO (STAA) has a net profit margin of -33.6%. The company is currently unprofitable.
STAAR SURGICAL CO (STAA) generated $-40 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
STAAR SURGICAL CO (STAA) reported earnings per share (EPS) of $-1.62 in its most recent fiscal year.
STAAR SURGICAL CO (STAA) has a 5-year average gross margin of 80.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for STAAR SURGICAL CO (STAA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.